Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥11.57 Million ≈ $1.69 Million USD) by net assets (CN¥2.26 Billion ≈ $330.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Hubei Biocause Heilen Pharmaceutical Co. market capitalisation for the company's overall valuation and market capitalisation.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. ranked by their cash flow conversion efficiency. Explore earnings quality score of Hubei Biocause Heilen Pharmaceutical Co. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Hi-tec Enterprise Co Ltd
TWO:5439
|
0.178x |
|
Shenzhen Urovo Technology Co Ltd
SHE:300531
|
0.059x |
|
Ulker Biskuvi Sanayi AS
IS:ULKER
|
0.050x |
|
Southern Cable Group Bhd
KLSE:0225
|
0.036x |
|
BAE Systems plc
LSE:BA
|
0.265x |
|
Bajaj Consumer Care Limited
NSE:BAJAJCON
|
0.105x |
|
ZENTIVA S.A.
RO:SCD
|
0.012x |
|
N-Able Inc
NYSE:NABL
|
0.022x |
Annual Cash Flow Conversion Efficiency for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025. View 301211 live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.27 Billion ≈ $332.64 Million |
CN¥7.55 Million ≈ $1.10 Million |
0.003x | -92.01% |
| 2024-12-31 | CN¥2.31 Billion ≈ $337.98 Million |
CN¥96.07 Million ≈ $14.06 Million |
0.042x | -28.48% |
| 2023-12-31 | CN¥2.36 Billion ≈ $344.86 Million |
CN¥137.06 Million ≈ $20.06 Million |
0.058x | -47.21% |
| 2022-12-31 | CN¥2.28 Billion ≈ $333.12 Million |
CN¥250.79 Million ≈ $36.70 Million |
0.110x | +97.51% |
| 2021-12-31 | CN¥2.22 Billion ≈ $325.26 Million |
CN¥123.98 Million ≈ $18.14 Million |
0.056x | -67.89% |
| 2020-12-31 | CN¥700.39 Million ≈ $102.49 Million |
CN¥121.67 Million ≈ $17.80 Million |
0.174x | -77.22% |
| 2019-12-31 | CN¥488.25 Million ≈ $71.45 Million |
CN¥372.33 Million ≈ $54.48 Million |
0.763x | +300.27% |
| 2018-12-31 | CN¥399.87 Million ≈ $58.51 Million |
CN¥76.18 Million ≈ $11.15 Million |
0.191x | +189.57% |
| 2017-12-31 | CN¥307.65 Million ≈ $45.02 Million |
CN¥-65.44 Million ≈ $-9.58 Million |
-0.213x | -- |
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including … Read more